{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-117540","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.018477+00:00","generated_at":"2026-05-16T15:44:47.698767+00:00","sec_items":["3.03","5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MetaVia announces 1-for-11 reverse stock split effective Dec 4, 2025 to meet Nasdaq listing requirements","bullets":["Reverse split at 1-for-11 ratio effective 5:00 p.m. ET Dec 4, 2025; begins split-adjusted trading Dec 5.","Outstanding shares reduced from ~25.4 million to ~2.3 million; authorized shares unchanged at 100 million.","Options, RSUs, and warrants adjusted proportionately; fractional shares rounded down for cash payment.","Approved by stockholders on June 30, 2025; board set ratio; new CUSIP 64132R 503; symbol remains MTVA.","MetaVia is a clinical-stage biotech focused on cardiometabolic diseases; no financial results reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-117540","json":"https://secwatch.observer/filing/0001104659-25-117540.json","markdown":"https://secwatch.observer/filing/0001104659-25-117540.md","text":"https://secwatch.observer/filing/0001104659-25-117540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465925117540/0001104659-25-117540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465925117540/mtva-20251202x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:44:47.698767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37e068c2104d4bd6bf1adc152a8f90f9705b0391","claim":"MetaVia Inc.: Amendment to Certificate of Incorporation to effect a 1-for-11 reverse stock split of common stock (effective 2025-12-04).","evidence_excerpt":"On December 2, 2025, the Company filed with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”) a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465925117540/0001104659-25-117540-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-12-04"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}